losatuxizumab vedotin

Losatuxizumab vedotin is a second-generation antibody-drug conjugate (ADC) designed to target the epidermal growth factor receptor (EGFR). It consists of a chimeric/humanized IgG1 monoclonal antibody directed against EGFR, conjugated via a linker to the cytotoxic payload monomethyl auristatin E (MMAE), a microtubule inhibitor. The drug was developed for the treatment of EGFR-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, glioblastoma multiforme, colon cancer, and breast cancer. Its mechanism involves binding to EGFR on tumor cells; upon internalization, MMAE is released intracellularly to induce cell death by disrupting microtubule dynamics. Clinical development was halted in early-phase trials due to high rates of infusion-related reactions[1][2][3][5].

Other names

losatuxizumab vedotin